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were involved in the study, which focused on the French
public mental health care system. Each service was classi-
fied according to the ESMS and data were collected on
service use. The data for each catchment area were aggre-
gated in residential use, structured day activities, continu-
ous out patient care and emergency out patient care, then
a cluster analysis was performed. The ESMS classifica-
tion of the services based on function was compared to
the official French description of services. RESULTS:
Four classes were identified: Class 1 high activity in all
services, class 2 low activity in all services, class 3 low ac-
tivity in continuous ambulatory care, class 4 high activity
in continuous ambulatory care. The ESMS confirmed the
consistency between the French official description of the
services’ missions and the actual activity. 10% of the ser-
vices had at least one additional “non official” function.
The study showed that the ESMS was adapted for use in
France, but it requires expert supervision for large-scale
implementation. CONCLUSIONS: The ESMS proves to
be useful not only in mental health service research, but
can also bring the possibility to adjust for the catchment
area’s service profile in outcomes research.
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AWARe® is an Internet-based database designed to cap-
ture clinical and humanistic outcomes from diabetes
practice settings around the world. The main goal of
AWARe® is to better understand how patients with type
2 diabetes respond to different treatments in a naturalis-
tic environment. OBJECTIVE: To describe an innovative
method of collecting clinical, humanistic and economic
outcomes of patients with type 2 diabetes in a “real
world” practice setting. METHODS: The data collection
methods involve the electronic linkage of clinical infor-
mation and humanistic outcomes of patients with type 2
diabetes. Patients at least 18 years of age who are main-
tained on oral antidiabetic therapy are eligible to partici-
pate in AWARe®. As providers enter patients’ clinical in-
formation into the patient’s electronic medical record, the
data elements of interest are automatically transmitted to
a secure Internet site (Pharmacon EB-HealthTM) where the
data are stored and continuously updated. Data collected
in AWARe® include: demographic information, pre-
scription use, HbA1c, fasting plasma glucose, total cho-
lesterol, triglycerides, LDL, HDL, blood pressure, liver
function tests, the SF-36, and the Diabetes and Treatment
Satisfaction Questionnaire (DTSQ). Every six months,
participants use hand-held devices to complete the elec-
tronic versions of the SF-36 and the DTSQ. The results
from these surveys are instantaneously transmitted via
wireless technology to EB-HealthTM. CONCLUSION:
AWARe® permits immediate retrieval of clinical and hu-
manistic information from an Internet-based registry. In-
formation on the patient’s clinical progress may be con-
tinuously transmitted to EB-HealthTM, allowing researchers,
clinicians and administrators to perform “real time”
analyses of the clinical effectiveness of antidiabetic ther-
apy, as well as to determine its impact on patients’ qual-
ity of life and satisfaction with treatment. As AWARe® is
expanded to sites around the US and throughout the
world, it will provide valuable information on the impact
of the different treatments for type 2 diabetes on patients’
clinical, humanistic and economic outcomes.
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OBJECTIVES: Attention-deficit/hyperactivity disorder
(ADHD) is one of the most prevalent of childhood men-
tal disorders, and represents the most common reason
children are referred to mental health providers.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who use large-scale administrative databases to evalu-
ate quality of care for mental disorders and associated
patient outcomes. Purchasers of health care who provide
health services to patients with psychiatric disorders.
The presence of the disorder is associated with substan-
tial health resource utilization and costs. Although evi-
dence-based guidelines for the pharmacologic treatment
of ADHD are widely available, little is known about vari-
ation in provider prescribing practices, patient compli-
ance, and attendant patient health outcomes. This is espe-
cially problematic because psychostimulants, commonly
prescribed for ADHD as a daily regimen, are frequently
taken solely on an “as needed” basis to improve behav-
iors during school hours. We are currently conducting a
program of research using large-scale, national, inte-
grated pharmacy benefits and medical claims databases
to examine the quality of ADHD pharmacologic care, pa-
tient compliance, and associated patient outcomes. The
objectives of this workshop are to discuss the complexi-
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ties encountered and offer recommendations for using
such databases to examine provider prescribing prac-
tices, patient compliance, and outcomes of ADHD-related
care. The following methodological issues will be dis-
cussed: 1) determining the presence of specific psychiatric
disorders and their comorbidities from pharmacy benefits
databases; 2) using pharmacy benefits databases and pa-
tient telephone and mail surveys to distinguish discontin-
ued psychotropic treatment from patient noncompliance
and medication switching; 3) applying health services uti-
lization and pharmacy databases to determine small area
variation in ADHD care; 4) examining the impact of be-
havioral health care carve-outs on analyses of patient
outcomes; 5) employing findings to benchmark existing
quality of care, calculate rates of provider adherence to
guidelines, identify best practices, and evaluate impact of
interventions on outcomes of patients with ADHD.
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OBJECTIVES: The objectives of this workshop are to de-
scribe various types of linkable clinical and administra-
tive claims data, review selected case studies, and high-
light the strengths and limitations of these databases.
PARTICIPANTS WHO WOULD BENEFIT: Those in-
volved in planning, designing, implementing, and using
data from retrospective database studies would benefit
from this workshop.
Administrative claims are increasingly used for outcomes
research studies, despite known limitations associated
with data reliability and validity, and a lack of clinical
content. In recent years, efforts have been made to link
claims to other sources, such as disease registries and
clinical laboratory files, to create richer databases for re-
search purposes. These linked data sources offer the po-
tential for improved accuracy in case identification and
outcomes ascertainment. For example, study patients can
be selected based on their presence in a disease registry
instead of relying on diagnoses reported on medical claim
forms, and clinical laboratory files can be used to evalu-
ate the success or failure of therapy. In this workshop, we
will review, via case studies from oncology and diabetes,
the content of linkable clinical and claims databases, the
specific ways in which such data have been used in pub-
lished outcomes studies, and the remaining limitations of
this record linkage approach. Participants will learn how
clinical data can be applied to strengthen studies of treat-
ment costs and the burden of illness, and they will gain
an appreciation of the improvements that linked data
sources can make to the pharmacoeconomics and out-
comes research fields. One case study will review applica-
tions of the SEER-Medicare database, which includes a
linkage between cancer registry data and Medicare ad-
ministrative claims for approximately 14% of U.S. cancer
cases across 17 diverse regions. The other illustration will
describe published studies of the economic benefits of im-
proving glycemic control among diabetes patients, in
which claims data from several managed-care organiza-
tions were linked to glycosylated hemoglobin test results.
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OBJECTIVES: The purposes of the workshop are to
demonstrate a systematic method to compare published
models developed for a same disease and to point out the
importance of validation of model structure, data input
and outcomes.
PARTICIPANTS WHO WOULD BENEFIT: Pharmaco-
economic and outcomes researchers involved in modeling
and/or in the area of DVT.
In the clinical and health economic literature, 11 different
models from different researchers are published in the
area of DVT prevention with heparins. These models
generally compare standard heparin with one of the low
molecular weight heparins in order to assess the health
economic consequences of better prevention at a higher
price. All models differ in many aspects of study design
and methodology: perspective, target audience, patient
population, patient subpopulations, choice of compara-
tor(s) and justification of this choice, medical manage-
ment patterns and corresponding decision trees, clinical
data input and reporting, economic data input and re-
porting, dealing with uncertainties, validation, conclu-
sions and extrapolations. This lack of uniformity in de-
sign and methods within a same research topic leads to
incomparable outcomes and conclusions. The workshop
is designed to discuss with the audience the strengths and
weaknesses of all models, and to have the audience sug-
gest solutions for better design, reporting and communi-
cations of results in this area and for decision models in
general. A novel consensus method, leading to a new
model, attempting to bring together the best elements of ex-
isting models, is proposed for discussion with the audience.
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